Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAAS blockade in type 2 diabetes with sodium restriction and hydrochlorothiazide
NL-OMON35646Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lisinopril and hydrochlorothiazide in diabetic glomerulosclerosis, hypertension (HTN) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by University Medical Center Groningen. Primary endpoints: Albuminuria response and Blood pressure response. Started Dec 2009; status: active, not recruiting.
02
Drugs
lisinoprilhydrochlorothiazide
03
Conditions
diabetic glomerulosclerosishypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON35646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35646.